You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI

    SBC: ASTROCYTE PHARMACEUTICALS INC.            Topic: 105

    DESCRIPTION provided by applicant Traumatic brain injuries TBI are an area of significant unmet need with no approved therapeutics and a national burden of $ billion annually Astrocyte Pharmaceuticals is developing a small molecule pharmaceutical agent that would be administered by intravenous injection by emergency responders or a medical professional within hours of injury to limit n ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Astroglial EAAT2 Changes in Live TBI Brain Determined by PET Imaging

    SBC: RIO PHARMACEUTICALS, INC.            Topic: NINDS

    PROJECT SUMMARYTraumatic Brain InjuryTBIis one of the most significant Public Health trauma diseases of our timeDiagnoses of various TBI forms rely on patient self reportingestablished clinical rating scalesand multimodality imaging to an extentTBI elicits complexheterogeneous pathological eventsincluding mechanical injuryhemorrhageand progressive secondary processes such as central and peripheral ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. A Structural Brain MRI Dementia Forecast Tool

    SBC: CORTICOMETRICS LLC            Topic: NIA

    DESCRIPTION provided by applicant Alzheimerandapos s disease AD the most common type of dementia is a devastating disease with no available treatment or prevention The current lifetime risk for a year old individual is estimated to be around Given current projections over million individuals will be diagnosed with Alzheimerandapos s disease by As the development of the ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. A Systematic Medical Approach to Reward Transformation SMART for Brain Health in Opioid Use Disorder

    SBC: Versa Integrated Solutions, Inc.            Topic: 102

    Summary In recent years opioid use disorder OUD and deaths due to opiate overdose e g with heroin fentanyl oxycodone in suburban and rural non minority groups has created an urgency for approaches to stem this epidemic but the rise in OUD and opiate overdose deaths has occurred in inner cities at similar rates Heroin misuse and addiction are persistent problems in African American commu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. A System for Rapid PCR, Mutation Scanning and Genotyping

    SBC: IDAHO TECHNOLOGY            Topic: N/A

    DESCRIPTION (provided by applicant): Our objective is to provide a closed-tube system for rapid PCR, mutation scanning and genotyping that does not require fluorescently-labeled probes. For many genetic diseases, it is difficult and expensive to screen for all possible mutations that may cause the disease. We propose a relatively simple solution for rapid amplification, scanning and genotyping in ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  6. A System for Rapid PCR, Mutation Scanning and Genotyping

    SBC: IDAHO TECHNOLOGY            Topic: N/A

    DESCRIPTION (provided by applicant): Our objective is to provide a closed-tube system for rapid PCR, mutation scanning and genotyping that does not require fluorescently-labeled probes. For many genetic diseases, it is difficult and expensive to screen for all possible mutations that may cause the disease. We propose a relatively simple solution for rapid amplification, scanning and genotyping in ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  7. A targeted peptide for PET imaging of cancer

    SBC: ATTENUON, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): ATN-161 (Ac-PHSCN-NH2) is a five amino acid peptide with potent anti-tumor, anti-angiogenic and anti-metastatic activity that specifically localizes to tumor cells and tumor endothelium. ATN-1 61 binds to several fully activated integrins which are involved in angiogenesis, metastasis and tumor growth and are present in both tumor and angiogenic endothelial ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  8. A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 1

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    ABSTRACTLyme disease, the most common vector-borne illness in North America, is caused by the spirochete B. burgdorferi. Infection begins in the skin following an infected tick-bite and acute illness is characterized by headache, fever and myalgia. Currently, there is no human vaccine against Lyme disease and therapeutic administration of antibiotics remains the recommended treatment option. In th ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. A Thermo-responsive Biopharmaceutical to Enhance the Tear Production of Lacritin

    SBC: EYERX RESEARCH, INC.            Topic: NEI

    Project Summary/Abstract Ocular pharmaceuticals predominantly use the topical route of administration, which involves a number of benefits and limitations when compared to systemic drug routes. A major limitation of the ocular topical route is the rapid loss of drug via tearing and nasolacrimal drainage, requiring the use of frequent dosing and high drug concentrations that then create formulation ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. A Tool for Research on Emotion in Naturally Occurring Speech

    SBC: Converspeech LLC            Topic: NLM

    DESCRIPTION provided by applicant A Tool for Research on Emotion in Naturally Occurring Speech It is now widely accepted that defects or limitations in emotion processing underlie many disorders such as anxiety depression bipolar and eating disorders If bio behavioral markers of emotions could be found researchers would have the basis for investigating emotions in both normal mental functi ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government